Physician profile
Christopher E Andrade
NPI 1194112359
$3,278.71
in general payments reported to CMS, 2019-2025
16 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $877 · 2021: $161 · 2022: $567 · 2023: $549 · 2024: $263 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,248.13 | 2019-2024 | Jardiance |
| Abbvie INC. | $519.95 | 2021-2025 | Skyrizi, Rinvoq |
| Conmed Corporation | $212.36 | 2023-2025 | Conmed Generators, Conmed Biliary |
| Astrazeneca Pharmaceuticals LP | $166.58 | 2019-2020 | |
| Novo Nordisk INC | $142.77 | 2019-2020 | |
| Lilly USA, LLC | $139.78 | 2020-2024 | Mounjaro |
| Olympus America INC. | $129.97 | 2023 | Visiglide, Evis Exera Lll Colonovideoscope |
| Paratek Pharmaceuticals, INC. | $124.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.09 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $122.47 | 2022 | |
| Gilead Sciences, INC. | $116.85 | 2022 | |
| Glaxosmithkline, LLC. | $115.53 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $47.81 | 2021-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $33.18 | 2019 | |
| Amgen INC. | $20.54 | 2023 | Avsola, Amjevita |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $15.12 | 2025 | Injection Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.